Polaryx Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Polaryx Therapeutics, Inc.'s yearly results, compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
—Data incomplete
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
—Data incomplete
Cash Cushion Ratio
—Data incomplete
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (9)
Polaryx Therapeutics, Inc. made a loss over the last year. Polaryx Therapeutics, Inc. owes $0.07 for every $1 it owns. Polaryx Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossPolaryx Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
8.84The share price is 8.84 times Polaryx Therapeutics, Inc.'s book value per share, higher than 85% of Healthcare companies in United States.
Market cap
$97 MThe total market value of all of Polaryx Therapeutics, Inc.'s shares at today's price (share price × number of shares), smaller than 66% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
$11 MWhat Polaryx Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$0.22Net worth divided by the number of shares. The share price of $1.94 is 8.8 times this, which is the P/B above.
Return on equity (ROE)
-96.6%Polaryx Therapeutics, Inc. lost 96.6% of its shareholders' money over the last year, lower than 70% of Healthcare companies in United States.
Owes vs Owns
0.07×Polaryx Therapeutics, Inc. owes $0.07 for every $1 it owns (low), lower than 92% of Healthcare companies in United States.
Dividend yield
NonePolaryx Therapeutics, Inc. does not currently pay a dividend.
Profit growth
LossPolaryx Therapeutics, Inc. made a loss in each of the last two years.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Polaryx Therapeutics, Inc.: $97 M ÷ $11 M (30 Jun 2026) = 8.8.
What is Polaryx Therapeutics, Inc.'s return on equity?
Polaryx Therapeutics, Inc. lost 96.6% of its shareholders' money over the last year, lower than 70% of Healthcare companies in United States.
How much does Polaryx Therapeutics, Inc. owe compared with what it owns?
Polaryx Therapeutics, Inc. owes $0.07 for every $1 it owns (low), lower than 92% of Healthcare companies in United States.
Does Polaryx Therapeutics, Inc. pay a dividend?
No. Polaryx Therapeutics, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.